Fund moves
2.77MShares reported
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
IMMX · NASDAQ · Pharmaceutical Preparations
Immix Biopharma (IMMX) · oqro.io/stocks/IMMX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$7.20−0.28 (−3.74%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
No open-market purchase by an insider of Immix Biopharma was filed in the last 90 days. The latest on record was on Sep 17, 2025.
Since 2021, Immix Biopharma insiders reported 40 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 5 different years, most recently 2025.
No open-market sale by an insider of Immix Biopharma (IMMX) was filed with the SEC in the last 90 days.
No trade in Immix Biopharma (IMMX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+78.2% (+$3.16) from Nov 17, 2025 to Nov 17, 2026 · adjusted daily closes
Adjusted close went from $4.04 on Nov 17, 2025 to $7.20 on Nov 17, 2026 (+78.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Los Angeles, Ca.
Last 12 months
+78.2%
Market value
$603M
S&P 500 +10.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 11.3M shares sold short (13.4% of shares outstanding), +5.1% vs the previous count, 9.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$45.2M
This quarter −$12.4M, a year earlier −$6.28M
Net debt
—
Debt —, cash $320M, at Sep 30, 2026
Net income, last 12 months
−$46.2M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Sep 17, 2025 · filed the same day
Since the trade +267.4% · S&P 500 +11.1% · to Nov 17
The CEO of Immix Biopharma paid $5K out of pocket for Immix Biopharma shares. 1 other person at Immix Biopharma bought some too, in the same month.
Insider buying
Traded Sep 16, 2025 · filed 1 day later
Since the trade +260.0% · S&P 500 +11.0% · to Nov 17
The CFO of Immix Biopharma paid $5.1K out of pocket for Immix Biopharma shares. 1 other person at Immix Biopharma bought some too, in the same month.
Fund moves
From a 13F filed Aug 15, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Immix Biopharma reported 40 open-market purchases and 1 sale since 2021; purchases in 5 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $20K4×4 trades | — |
| 2024 | $237K13×13 trades | — |
| 2023 | $655K13×13 trades | — |
| 2022 | $10K4×4 trades | $5501×1 trade |
| 2021 | $422K6×6 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 13, 2025, IMMX is up 99.4% and the index fund is up 9.0%: 90 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much IMMX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.